News

The net income in the first quarter of fiscal 2009 is primarily the result of a 23% decrease in marketing, general and administrative expenses and a 23% decrease

The company has reported net sales of $5.07 million for the first quarter of 2009 compared to $5.76 million for the same period of 2008. Michael Perry, CEO

Kanan brings two decades of financial experience to Sigma-Aldrich. His most recent position at ArvinMeritor was vice president finance-light vehicle systems since 2006. His prior experience at ArvinMeritor

NovaBay Pharmaceuticals, a clinical stage biopharmaceutical company, has reported a net loss of $1.5m, or $0.07 per share, for the fourth quarter of 2008, compared to a net

Bioniche Life Sciences, a research-based biopharmaceutical company, has completed recruitment in its initial Phase III registration trial evaluating Urocidin in the treatment of non-muscle-invasive bladder cancer that is

Wyeth Pharmaceuticals, a division of Wyeth, has submitted a biologic license application to the FDA for Prevnar 13, pneumococcal 13-valent conjugate vaccine. The Prevnar 13 submission to the

ReNeuron Group, a UK-based stem cell company, has reported positive preclinical efficacy data with its lead CTX stem cell line in a model of peripheral arterial disease, a

Vasomedical, a manufacturer of enhanced external counterpulsation therapy systems, has received the FDA 510(k) clearance to market Vasomedical-Biox 1305 ECG Holter monitor and CB series ambulatory ECG analysis

GlaxoSmithKline has submitted two simultaneous regulatory applications to expand the use of Tyverb/Tykerb. If approved, Tyverb/Tykerb could be used as a first-line therapy regimen combined with anti-hormonal therapy